Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.31 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2343366 | 0.91 | PTGDR2 (0.35) | RENMKNK2PTGDR2MGAT2HTR7 | |
| SCHEMBL4582330 | 0.90 | REN (0.36) | RENPDE4BPTGDR2TMEM97SIGMAR1 | |
| SCHEMBL2339965 | 0.89 | REN (0.40) | REN | |
| SCHEMBL2342157 | 0.88 | REN (0.39) | RENMKNK2 | |
| SCHEMBL2339007 | 0.88 | MKNK2 (0.33) | MKNK2PTGDR2 | |
| SCHEMBL2337934 | 0.87 | REN (0.36) | RENMKNK2PTGDR2 | |
| SCHEMBL4583558 | 0.86 | REN (0.44) | REN | |
| SCHEMBL2337671 | 0.86 | REN (0.44) | REN | |
| SCHEMBL2337532 | 0.86 | MMP9 (0.36) | RENPDE4BTMEM97SIGMAR1 | |
| SCHEMBL3913491 | 0.86 | MMP9 (0.36) | RENPDE4BTMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776359-B1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-27 | — | — | US | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | REN, AGTR1, ACE | REN 1/4885MKNK2 2860/4885PDE4B 642/4885 |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | REN 119/4885MKNK2 3536/4885PDE4B 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.